Prothena Corp. (PRTA) Adds Sanjiv Patel to Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- US futures steady as oil retreats ahead of earnings deluge, Fed decision
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil slips but stays near six-month highs on Saudi attacks
- BofA flags further downside risk for stocks, yields and dollar
Prothena Announces Appointment of Sanjiv Patel, MBBS, to its Board of Directors
May 20, 2021 4:05 PM EDTDUBLIN, Ireland, May 20, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ: PRTA), a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today the appointment of Sanjiv K. Patel, MBBS, MA, MBA, to its Board of Directors.
Sanjiv is an experienced leader with significant industry experience that uniquely positions him to guide us as we look towards transitioning to a fully integrated research, development and commercial biotechnology company, commented Lars Ekman, MD, PhD, Prothenas Chairman. We welcome Sanjiv to our Board and look forward... More



